


PHARMACEUTICAL 2022



SELLAS Life Sciences Group Inc. Rank 388 of 475





PHARMACEUTICAL 2022



SELLAS Life Sciences Group Inc. Rank 388 of 475

The relative strengths and weaknesses of SELLAS Life Sciences Group Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SELLAS Life Sciences Group Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 122% points. The greatest weakness of SELLAS Life Sciences Group Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 244% points.

The company's Economic Capital Ratio, given in the ranking table, is -383%, being 106% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	23,044
Cost of Goods Sold	200
Intangible Assets	1,914
Liabilities, Current	4,982
Liabilities, Non-Current	610
Other Assets	1,317
Other Compr. Net Income	0
Other Expenses	5,463
Other Liabilities	336
Other Net Income	4,358
Property and Equipment	0
Research and Development	15,674
Revenues	7,600
Selling, General and Administrative Expense	11,320

Output Variable	Value in 1000 USD
Assets	26,275
Liabilities	5,928
Expenses	32,657
Stockholders Equity	20,347
Net Income	-20,699
Comprehensive Net Income	-20,699
Economic Capital Ratio	-383%